Emergent BioSolutions / EBS

About Emergent BioSolutions

2273 Research Blvd., Suite 400, Rockville, Md. 20850
www.emergentbiosolutions.com | 301-795-1800 | Founded: 1998

Industry: Biotechnology | Category: Public Companies

The company's plan to diversify beyond its crown jewel, the only federally approved anthrax vaccine, failed last year when its bid to buy flu-vaccine maker Protein Sciences was scuttled. The companies were not able to close the deal, which ended in a lawsuit. Emergent plans to pursue other acquisitions. It formed a joint venture with the University of Oxford to develop a tuberculosis vaccine and is also working on a typhoid vaccine.

2008 Financial Data

Revenues: $178,554,000 | Net Income: $20,682,000
Asssets: $290,788,000 | Earnings Per Share: $0.68
Stockholder Equity: $199,349,000 | Annual Dividend: $0.00
Total employees: 587 | Local employees: 193